Nigeria GMP: Labelling Control, Complaint Handling and Recall Requirements

1. Key takeaways

Within the GMP guideline DER-GDL-025-00, three clusters of clauses are the ones most likely to be probed during a factory inspection, yet the ones most often neglected inside companies. They concern labelling control, complaint handling and recall. Understanding each cluster before an inspector raises it is the most efficient way to prepare.

First, UDI is a GMP-level requirement, not merely a labelling-level option. §12.6 provides that devices must have a UDI (Unique Device Identification) to enhance traceability, and the UDI must be indicated on the packaging. This means UDI readiness is tested through quality system documents and records, not only through artwork review at registration stage.

Second, label changes must be traceable down to version, rationale and approval. §12.2 requires the manufacturer to maintain an SOP for the creation, approval and control of labelling materials; detailed specifications for labels (content, format, location); a master record for each device listing all labelling components and their versions; documented records of any label change, including rationale and approval; physical or electronic samples of current and superseded labels; records of distribution times and destinations of labelled product; documentation of labelling-related complaints and their investigation; training evidence for labelling personnel; and copies of labels submitted to the regulatory authority and related correspondence. The list is long by design: it makes labelling a fully auditable history rather than a set of printed files.

Third, complaints and recall are system clauses, not case-by-case actions. §13.1 requires adequate resources and trained personnel; written procedures covering the receipt, investigation and recording of complaints; documented root cause analysis; manufacturer assurance of CAPA effectiveness and monitoring; timely recording and review of all complaints; thorough investigation of causes; detailed records of complaints, investigations and actions taken; and timely communication with the regulatory authority and relevant parties. §13.2 requires a written recall procedure; risk evaluation of defective product and determination of recall scope; mock recalls; and, upon discovery of a quality defect, initiation of the recall, notification of the regulatory authority, medical professionals and customers, execution of the recall, and monitoring of progress to ensure all affected product is accounted for.

2. Legal basis

The division of labour between these instruments is worth noting. The GMP guideline governs what the company must be able to do internally; the recall guideline governs how a recall is classified, communicated and monitored at the official level; and the Regulations anchor the post-market obligations in law.

3. Expert insights

Insight one: §12.9 contains a hard requirement to destroy rather than return unused labels. §12.9 provides that unused labels bearing pre-coded information (serial numbers, production dates, expiry dates, control numbers) should be destroyed, not returned to storage — especially when packaging or labelling different models of the same product. The clause targets the mixed-batch risk that arises when leftover pre-printed labels migrate between production runs. Inspectors will look for destruction records, so the destruction step should be a controlled, documented operation with named responsibility, not an informal housekeeping practice.

Insight two: §12.10 gives explicit handling for partially sterile devices. §12.10 requires particular attention to the labelling of sterile devices; devices that are not wholly sterile must be labelled so that the user is correctly informed which parts of the packaging are sterile; and for single-use sterile devices, the manufacturer must state that the device must not be resterilised or reused. For exporters of procedure kits, this is a common trap: a kit may contain both sterile and non-sterile components, and the label must make that distinction visible rather than presenting the whole kit as sterile.

Insight three: the §12.8 separation of labelling and packaging operations has an exception. §12.8 requires labelling and packaging operations to be separated to prevent mix-ups between similar products or labels, which may be achieved through physical or spatial separation, or by scheduling different devices at different times; separation is not required when confusion is impossible (for example, where a label can only fit a specific device); and access to labels should be limited to authorised personnel. Companies may use an impossibility-of-confusion argument to reduce redesign costs, but the argument must be written down and justified, not merely asserted verbally during an inspection.

Insight four: the GMP recall clauses and the recall guideline form a closed loop of system plus procedure. GMP §13.2 governs the company internal recall procedure and its drills; PMS-GDL-020-00 governs the official classification, communication and progress monitoring (including recall letters, press releases, and the PMS Directorate advising the Director-General). Neither alone is sufficient: without the internal procedure, drills cannot be executed; without the external process, notifications will be non-conforming. Companies should map their internal recall SOP step by step against §4, §5 and §6 of the recall guideline so both clocks run in parallel during a real event.

Insight five: the complaint record retention period is the longer of two one-year periods, not a fixed term. §13.1(f) requires records to be kept for at least 1 year beyond the device expiry date, or 1 year from receipt of the complaint, whichever is longer. For implantable devices with long expiry periods, actual retention will therefore run well beyond one year. The practical consequence is that retention periods must be computed per product line from expiry data, and storage arrangements must be able to hold complaint files for that calculated duration.

4. Practical recommendations

1. Implement UDI down to packaging level and make it traceable within the DHR.
2. Maintain a label master record and a change ledger capturing version, rationale, approver and effective date for every change.
3. Route pre-coded unused labels through a documented destruction process with retained records.
4. Conduct at least one mock recall per year and record the reconciliation rate as the key performance indicator.
5. Set complaint record retention to a floor of one year beyond expiry, extending it further for long-shelf-life products.

None of these measures requires new technology; they require ownership, records and rehearsal. Assign each item to a named function, verify it quarterly, and the inspection questions in this area become routine demonstrations of existing practice.

5. Verification checklist

• □ UDI is indicated on the packaging (§12.6).
• □ Labelling SOP, master record and change ledger (rationale plus approval) are complete.
• □ Pre-coded unused labels are destroyed and recorded per §12.9.
• □ Sterile device labelling follows §12.10 (partial sterility; no resterilisation or reuse).
• □ Mock recalls are conducted periodically with retained records.
• □ Complaint record retention meets the one year beyond expiry floor.

Regulatory information verified as of 29 October 2026. All provisions cited above were checked against the GMP guideline (DER-GDL-025-00 §12.2, §12.6, §12.8–§12.10, §13.1–§13.2), the recall guideline (PMS-GDL-020-00) and the Regulations (S.I. No. 42 of 2024, Regulations 8(1)(e) and 12) as published on the NAFDAC website; this review is refreshed whenever the regulations are updated.

GRZAN supports manufacturers entering the Nigerian market with registration documentation and conformity files, including classification determination, registration pathway selection, technical documentation to the IMDRF ToC, GMP and foreign inspection readiness, advertisement permits, vigilance and PMS reporting, change management and renewal. Local resources in Nigeria cover licensed import entities and authorised representative services, NAPAMS online submission, dossier screening permit liaison, import permits, sample delivery and laboratory analysis support. Contact: hito.lin@grzan.cn; website www.grzan.cn.